Payment overview · 2025
General Payments
$1,357.69
26 reported records · 10 companies
Healthcare provider profile · identity verified
Peter H. Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LOS ANGELES, CA · NPI 1932237013
Verified facts
What the public records show
CMS Open Payments records show Peter H. Lee, M.D. received $1,357.69 in general payments during 2025 across 26 reported records.
AKEBIA THERAPEUTICS INC accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Lokelma.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auryxia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $317.07 | 23.4% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $293.13 | 21.6% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $250.71 | 18.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.16 | 10.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.89 | 9.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.35 | 6.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.96 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.26 | 3.7% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.18 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.98 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,357.69 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $317.07 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $173.41 | 6 | 2025 |
Source payment records
|
|||||
| Axios Normalized: axios |
Device | Boston Scientific Corporation | $138.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $122.89 | 1 | 2025 |
Source payment records
|
|||||
| XPHOZAH 30 MG Normalized: xphozah 30 mg |
Drug | Ardelyx, Inc. | $119.72 | 1 | 2025 |
Source payment records
|
|||||
| OverStitch Endoscopic Suturing System Normalized: overstitch endoscopic suturing system |
Device | Boston Scientific Corporation | $112.15 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $108.68 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.96 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.26 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 189 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 84 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jardiance | Empagliflozin | 189 | 37 |
| Tradjenta | Linagliptin | 180 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 32 |
| Losartan Potassium | Losartan Potassium | 126 | 33 |
| Vascepa | Icosapent Ethyl | 121 | 18 |
| Allopurinol | Allopurinol | 118 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 84 | 11 |
| Kerendia | Finerenone | 84 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 80 | 15 |
| Procrit | Epoetin Alfa | 75 | 13 |
| Furosemide | Furosemide | 67 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 62 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 52 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Renvela | Sevelamer Carbonate | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Gabapentin | Gabapentin | 43 | suppressed |
| Dutasteride | Dutasteride | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | 11 |
| Omeprazole | Omeprazole | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 16 | suppressed |
| Auryxia | Ferric Citrate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,357.69 · 26 records | AKEBIA THERAPEUTICS INC | Axios, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LOKELMA, OverStitch Endoscopic Suturing System, Ozempic, RAYALDEE, REPATHA, Rybelsus, Vafseo, XPHOZAH 30 MG | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error